School of Nursing, College of Nursing, Chung Shan Medical University, Taichung, Taiwan.
Reprod Sci. 2009 Jun;16(6):610-7. doi: 10.1177/1933719109332829. Epub 2009 Mar 11.
The objective was to compare the expression of plasma stromal cell-derived factor 1 and the gene polymorphism in patients with pelvic inflammatory disease and healthy controls. The enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were, respectively, used to measure the plasma stromal cell-derived factor 1alpha level and stromal cell-derived factor 1 polymorphism in 50 healthy controls and in 44 patients with pelvic inflammatory disease before and after they received routine treatment protocols. The level of plasma stromal cell-derived factor 1alpha was elevated in patients with pelvic inflammatory disease compared to normal controls and decreased significantly after treatment. There were significant correlations between plasma stromal cell-derived factor 1alpha level and neutrophil count as well as between stromal cell-derived factor 1alpha level and white blood cell count in patients with pelvic inflammatory disease. There was no significantly different distribution of stromal cell-derived factor 1 genotypes between patients with pelvic inflammatory disease and normal controls. Patients with pelvic inflammatory disease having stromal cell-derived factor 1-3'A allele were associated with significantly elevated plasma stromal cell-derived factor 1alpha concentration compared to patients with pelvic inflammatory disease having G/G homozygous alleles (P < .02). In normal controls, there was no significant difference in the plasma stromal cell-derived factor 1 level between individuals with and without stromal cell-derived factor 1-3'A allele. When the cutoff level of plasma stromal cell-derived factor 1alpha level was determined to be 2192 pg/mL based on receiver-operating characteristic curve, the sensitivity, specificity, positive predictive value, and negative predictive value as well as accuracy were 77.3%, 88.0%, 85.0%, 81.5%, and 83.0%. In conclusion, when the cutoff level was determined to be 2192 pg/mL, plasma stromal cell-derived factor 1alpha level can be used to predict pelvic inflammatory disease.
比较盆腔炎患者与健康对照者血浆基质细胞衍生因子 1 的表达及其基因多态性。采用酶联免疫吸附试验和聚合酶链反应-限制性片段长度多态性分析，分别检测 50 例健康对照者和 44 例盆腔炎患者常规治疗前后的血浆基质细胞衍生因子 1α水平和基质细胞衍生因子 1 多态性。与正常对照组相比，盆腔炎患者的血浆基质细胞衍生因子 1α水平升高，治疗后明显下降。盆腔炎患者的血浆基质细胞衍生因子 1α水平与中性粒细胞计数以及白细胞计数呈显著正相关。盆腔炎患者与正常对照组基质细胞衍生因子 1 基因型分布无显著差异。与 G/G 纯合子相比，盆腔炎患者携带基质细胞衍生因子 1-3'A 等位基因者的血浆基质细胞衍生因子 1α浓度显著升高（P <.02）。在正常对照组中，携带和不携带基质细胞衍生因子 1-3'A 等位基因者的血浆基质细胞衍生因子 1 水平无显著差异。根据受试者工作特征曲线确定血浆基质细胞衍生因子 1α水平的截断值为 2192 pg/ml 时，其灵敏度、特异度、阳性预测值、阴性预测值和准确率分别为 77.3%、88.0%、85.0%、81.5%和 83.0%。结论：当截断值为 2192 pg/ml 时，血浆基质细胞衍生因子 1α水平可用于预测盆腔炎。
